152 related articles for article (PubMed ID: 38862867)
1. Point-of-care gastric ultrasound: believing is seeing.
Sotiriou A; El-Boghdadly K
Can J Anaesth; 2024 Jun; ():. PubMed ID: 38862867
[No Abstract] [Full Text] [Related]
2. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
Sherwin M; Hamburger J; Katz D; DeMaria S
Can J Anaesth; 2023 Aug; 70(8):1300-1306. PubMed ID: 37466909
[TBL] [Abstract][Full Text] [Related]
3. Point of Care Ultrasonography to Monitor Decongestive Therapy in Heart Failure: Seeing is Believing.
Koratala A
POCUS J; 2022; 7(Kidney):14-16. PubMed ID: 36896105
[No Abstract] [Full Text] [Related]
4. Bridging the gap: understanding Belgian anesthesiologists' proficiency and training demands in gastric point-of-care ultrasound, a case-based survey.
Maseri A; Delhez Q; Dincq AS; Lacrosse D
BMC Med Educ; 2024 Apr; 24(1):383. PubMed ID: 38589900
[TBL] [Abstract][Full Text] [Related]
5. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
6. Point-of-Care Ultrasound (POCUS) for the Cardiothoracic Anesthesiologist.
Kalagara H; Coker B; Gerstein NS; Kukreja P; Deriy L; Pierce A; Townsley MM
J Cardiothorac Vasc Anesth; 2022 Apr; 36(4):1132-1147. PubMed ID: 33563532
[TBL] [Abstract][Full Text] [Related]
7. Gastric Point-of-Care Ultrasound in Acutely and Critically Ill Children (POCUS-ped): A Scoping Review.
Valla FV; Tume LN; Jotterand Chaparro C; Arnold P; Alrayashi W; Morice C; Nabialek T; Rouchaud A; Cercueil E; Bouvet L
Front Pediatr; 2022; 10():921863. PubMed ID: 35874585
[TBL] [Abstract][Full Text] [Related]
8. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
Iacobellis G; Villasante Fricke AC
J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
[TBL] [Abstract][Full Text] [Related]
9. Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.
Hodgson JA; Rivera-Rodriguez H; Wu P; Udani J; Weiss J
A A Pract; 2024 Mar; 18(3):e01762. PubMed ID: 38498670
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.
Avraham SA; Hossein J; Somri F; Hawash N; Hochman O
Anaesth Rep; 2024; 12(1):e12278. PubMed ID: 38225986
[TBL] [Abstract][Full Text] [Related]
11. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
12. Point-of-Care Gastric Ultrasound Confirms the Inaccuracy of Gastric Residual Volume Measurement by Aspiration in Critically Ill Children: GastriPed Study.
Valla FV; Cercueil E; Morice C; Tume LN; Bouvet L
Front Pediatr; 2022; 10():903944. PubMed ID: 35783320
[TBL] [Abstract][Full Text] [Related]
13. Point-of-care ultrasound in pediatric anesthesia: perioperative considerations.
Adler AC; Matisoff AJ; DiNardo JA; Miller-Hance WC
Curr Opin Anaesthesiol; 2020 Jun; 33(3):343-353. PubMed ID: 32324662
[TBL] [Abstract][Full Text] [Related]
14. Neonatal and paediatric point-of-care ultrasound review.
Pan S; Lin C; Tsui BCH
Australas J Ultrasound Med; 2023 Feb; 26(1):46-58. PubMed ID: 36960139
[TBL] [Abstract][Full Text] [Related]
15. Seeing Is Believing: Ultrasound in Pediatric Procedural Performance.
Fraga MV; Stoller JZ; Glau CL; De Luca D; Rempell RG; Wenger JL; Yek Kee C; Muhly WT; Boretsky K; Conlon TW
Pediatrics; 2019 Nov; 144(5):. PubMed ID: 31615954
[TBL] [Abstract][Full Text] [Related]
16. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
17. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
Wu F; Smith MR; Mueller AL; Klapman SA; Everett LL; Houle T; Kuo B; Hobai IA
Can J Anaesth; 2024 Mar; ():. PubMed ID: 38485835
[TBL] [Abstract][Full Text] [Related]
18. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Mahapatra MK; Karuppasamy M; Sahoo BM
Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
[TBL] [Abstract][Full Text] [Related]
20. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
